论文部分内容阅读
目的研究综合重症监护病房(ICU)患者肺部感染肠杆菌的耐药性特点,探索防控措施。方法采用回顾性调查方法,对某医院综合ICU住院病人肺部感染患者送检标本中肠杆菌科病原菌检测结果进行分析与评价。结果从该医院综合ICU住院病人肺部感染患者痰标本中共分离出肠杆菌科病原菌1 678株,主要是大肠埃希菌和肺炎克雷伯菌,构成比分别为56.38%和28.96%。痰标本分离的肠杆菌科病原菌对碳青霉烯类抗菌药物中的亚胺培南已经出现耐药菌株,但总敏感率仍然达到90%以上。肺部感染的肠杆菌科病原菌对多数抗菌药物普遍耐药。结论该综合ICU患者肺部感染肠杆菌科主要是大肠埃希菌和肺炎克雷伯菌,其对碳氢酶烯类已经出现耐药,应加强耐药菌监测和药敏试验,严格控制抗菌药物的应用。
Objective To study the drug resistance of Enterobacteriaceae in the lungs of patients in intensive care unit (ICU) and explore the prevention and control measures. Methods The retrospective investigation method was used to analyze and evaluate the results of Enterobacteriaceae pathogenic bacteria in the specimens of patients with pulmonary infection in inpatients with ICU in a hospital. Results A total of 1 678 Enterobacteriaceae pathogens were isolated from the sputum samples from patients with pulmonary infection in inpatients with intensive care unit (ICU) in the hospital. The main pathogens were Escherichia coli and Klebsiella pneumoniae with the proportions of 56.38% and 28.96%, respectively. Enterobacteriaceae isolated from sputum specimens have emerged resistant strains to imipenem in carbapenem-based antibiotics, but the total susceptibility still reaches over 90%. Enterobacteriaceae infections in the lungs are generally resistant to most antibiotics. Conclusion The pulmonary infection in the ICU patients with Enterobacteriaceae is mainly Escherichia coli and Klebsiella pneumoniae, which has resistance to hydrocarbon enzymes, drug resistance monitoring should be strengthened and susceptibility testing, strict control of antibacterial Application of drugs.